Definitive Healthcare (NASDAQ:DH) Shares Gap Up to $4.44

Shares of Definitive Healthcare Corp. (NASDAQ:DH) gapped up prior to trading on Tuesday . The stock had previously closed at $4.44, but opened at $4.65. Definitive Healthcare shares last traded at $4.70, with a volume of 26,577 shares traded.

Analyst Ratings Changes

Several analysts have recently weighed in on the stock. Morgan Stanley lowered their target price on shares of Definitive Healthcare from $9.00 to $5.00 and set an “equal weight” rating on the stock in a report on Tuesday, August 6th. Stifel Nicolaus dropped their target price on Definitive Healthcare from $9.50 to $7.50 and set a “buy” rating on the stock in a research report on Wednesday, July 31st. JPMorgan Chase & Co. cut Definitive Healthcare from a “neutral” rating to an “underweight” rating and reduced their price target for the company from $7.00 to $5.00 in a report on Wednesday, July 31st. Robert W. Baird decreased their price target on Definitive Healthcare from $6.00 to $5.00 and set a “neutral” rating on the stock in a research note on Wednesday, August 7th. Finally, BTIG Research assumed coverage on Definitive Healthcare in a research report on Tuesday. They issued a “buy” rating and a $7.00 price objective for the company. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat, Definitive Healthcare presently has an average rating of “Hold” and a consensus target price of $5.81.

Definitive Healthcare Stock Performance

The company has a debt-to-equity ratio of 0.27, a current ratio of 2.40 and a quick ratio of 2.40. The company has a market capitalization of $537.78 million, a PE ratio of -2.61, a P/E/G ratio of 6.38 and a beta of 1.33. The stock has a 50-day simple moving average of $4.65 and a 200 day simple moving average of $5.91.

Definitive Healthcare (NASDAQ:DH) last released its quarterly earnings data on Monday, August 5th. The company reported $0.09 EPS for the quarter, hitting the consensus estimate of $0.09. Definitive Healthcare had a negative net margin of 156.65% and a positive return on equity of 0.98%. The business had revenue of $63.70 million for the quarter, compared to analyst estimates of $63.19 million. During the same period in the previous year, the firm earned $0.08 EPS. The business’s revenue for the quarter was up 4.4% compared to the same quarter last year. Equities analysts anticipate that Definitive Healthcare Corp. will post 0.07 EPS for the current fiscal year.

Institutional Investors Weigh In On Definitive Healthcare

A number of institutional investors and hedge funds have recently bought and sold shares of DH. Sanctuary Advisors LLC acquired a new position in shares of Definitive Healthcare in the second quarter worth $85,000. Algert Global LLC purchased a new stake in Definitive Healthcare during the 2nd quarter worth about $1,265,000. Susquehanna Fundamental Investments LLC raised its stake in Definitive Healthcare by 1,031.3% in the 2nd quarter. Susquehanna Fundamental Investments LLC now owns 167,584 shares of the company’s stock valued at $915,000 after purchasing an additional 152,770 shares during the last quarter. The Manufacturers Life Insurance Company lifted its holdings in Definitive Healthcare by 17.0% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 22,896 shares of the company’s stock valued at $125,000 after purchasing an additional 3,332 shares in the last quarter. Finally, Millennium Management LLC acquired a new stake in shares of Definitive Healthcare during the 2nd quarter worth about $9,283,000. Hedge funds and other institutional investors own 98.67% of the company’s stock.

Definitive Healthcare Company Profile

Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution.